Status: Roll-over study, not opened for enrollment
ClinicalTrials.gov Identifier: NCT02745119
GX30191: A multi-center, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with GA secondary to AMD who have completed a Roche-Sponsored Study
Condition: Geographic Atrophy
Study Type: Interventional
Duration: 96 weeks
Eligibility:
For additional information, please click here
Back to Clinical Research